Page 239 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Confirmation practice in pharmacogenetic testing
18. Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459-1467.
19. Deenen MJ, Meulendijks D, Cats A, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016;34(3):227-234.
20. MO. Dutch Association for Medical Oncology. “Result survey screening for DPD deficiency”. In. Dutch Medical Oncology Journal. Vol 192016:12-15.
21. Henricks LM, Lunenburg CATC, de Man FM, et al. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer. 2018;107:60- 67.
22. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem. 2009;55(4):641-658.
23. van der Heiden IP, van der Werf M, Lindemans J, van Schaik RH. Sequencing: not always the “gold standard”. Clin Chem. 2004;50(1):248-249.
24. Blais J, Lavoie SB, Giroux S, et al. Risk of Misdiagnosis Due to Allele Dropout and False-Positive PCR Artifacts in Molecular Diagnostics: Analysis of 30,769 Genotypes. J Mol Diagn. 2015;17(5):505- 514.
25. FDA. Discussion Paper on Laboratory Developed Tests (LDTs). 2017.
26. EMA. Guideline on good pharmacogenomic practice 2018; EMA/CHMP/718998/712016 9
Committee for Medicinal Products for Human Use (CHMP). Available at: https://www.ema. europa.eu/documents/scientific-guideline/guideline-good-pharmacogenomic-practice-first- version_en.pdf. Accessed 11 October 2018.
27. Ten Brink MH, Van der Straaten T, Bouwsma H, Baak-Pablo R, Guchelaar HJ, Swen JJ. Pharmacogenetics in transplant patients: mind the mix. Clin Pharmacol Ther. 2013;94(4):443- 444.
28. Ten Brink MH, Bouwsma H, Baak-Pablo R, Guchelaar HJ, Van der Straaten T, Swen JJ. PKP- 016 Pharmacogenetics in allogeneic stem cell transplant patients: Mind the Mix Eur J Hosp Pharm. 2014;21(A143).
29. Scantamburlo G, Tziolia K, Zopf M, et al. Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays. Cell Physiol Biochem. 2017;43(6):2297-2309.
30. ExAC. Exome Aggregation Consortium. ExAC Browser (Beta). 2016; http://exac.broadinstitute. org/ Accessed 13/12/2017.
237